Gilead counterpunches AbbVie with CVS deal

Source: Seeking Alpha

6 Jan 2014

  • CVS Health (CVS -1.3%) bestows Preferred Status to Gilead Sciences’ (GILD+2.3%) Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) for the treatment of HCV infection. The pills will be the exclusive treatment option for beneficiaries on CVS’s Medicare, Medicaid and other drug benefit plans. AbbVie’s (ABBV-2.9%) Viekira Pak will be available only via a medical exception or prior authorization. Recently, AbbVie announced a similar deal with Express Scripts.
  • Previously: AbbVie’s new hepatitis C drug gets boost (Dec. 22, 2014)
This entry was posted in Hepatitis C, Pricing. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s